es104
mAbexperimentalBi-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 25, 2022 (NCT05167448)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
- Delta-like protein 4INHIBITOR
DLL4 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05167448 | Phase 1/Phase 2 (Phase 2) | Feb 25, 2022 | Elpiscience (Suzhou) Biopharma, Ltd. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Elpiscience (Suzhou) Biopharma, Ltd. | For profit | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1